CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Pangali Sanam Chief Legal Officer | Sale | −332 | $6.52 | $2K | 9,415 |
| 2026-11-02 | Bradley Mark Christopher Chief Development Officer | Sale | −623 | $6.52 | $4K | 47,910 |
| 2026-11-02 | Drappa Jorn Chief Medical Officer | Sale | −593 | $6.52 | $4K | 56,299 |
| 2026-11-02 | Goldstein David M Chief Scientific Officer | Sale | −629 | $6.52 | $4K | 30,341 |
| 2026-11-02 | Schroer John R. Chief Financial Officer | Sale | −794 | $6.52 | $5K | 23,924 |
| 2026-11-02 | Hardiman Roy C. Chief Business & Strategy Ofcr | Sale | −652 | $6.52 | $4K | 207,094 |
| 2026-09-08 | AKKARAJU SRINIVAS Director | Sale | −48,066 | $10.55 | $507K | 4,663,735 |
| 2026-09-08 | AKKARAJU SRINIVAS Director | Sale | −48,065 | $10.55 | $507K | 2,025,493 |
| 2026-09-08 | AKKARAJU SRINIVAS Director | Purchase | +273,291 | $10.63 | $2.9M | 4,937,026 |
| 2026-09-08 | AKKARAJU SRINIVAS Director | Purchase | +273,290 | $10.63 | $2.9M | 2,298,783 |
| 2026-09-04 | AKKARAJU SRINIVAS Director | Purchase | +220,070 | $11.17 | $2.5M | 4,711,801 |
| 2026-09-04 | AKKARAJU SRINIVAS Director | Purchase | +220,070 | $11.17 | $2.5M | 2,073,558 |
| 2026-08-03 | Pangali Sanam Chief Legal Officer | Sale | −1,364 | $26.37 | $36K | 9,747 |
| 2026-08-03 | Bradley Mark Christopher Chief Development Officer | Sale | −2,572 | $26.37 | $68K | 48,533 |
| 2026-08-03 | Drappa Jorn Chief Medical Officer | Sale | −2,447 | $26.37 | $65K | 56,892 |
| 2026-08-03 | Goldstein David M Chief Scientific Officer | Sale | −2,596 | $26.37 | $68K | 30,970 |
| 2026-08-03 | Schroer John R. Chief Financial Officer | Sale | −3,282 | $26.37 | $87K | 24,718 |
| 2026-08-03 | Hardiman Roy C. Chief Business & Strategy Ofcr | Sale | −2,692 | $26.37 | $71K | 207,746 |
| 2026-07-06 | Pangali Sanam Chief Legal Officer | Option exercise | +5,000 | $5.06 | $25K | 16,111 |
| 2026-07-06 | Pangali Sanam Chief Legal Officer | Sale | −5,000 | $28.00 | $140K | 11,111 |
Page 1 of 21 · 405 trades